Q1 results, Rs 149 Cr capex approved, leadership role change
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 20.3 pts more than Nifty Microcap 250 and 20.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aarti Pharmalabs Q1FY27 standalone revenue grew about 42 percent YoY to Rs 534.59 Cr; PAT jumped about 49 percent to Rs 71.31 Cr (EPS Rs 7.87). Board approved Rs 149 Cr capex for a new 405 KL intermediate block to be set up in one year, funded by internal accruals and borrowings. Rashesh Gogri to become Managing Director and Hetal Gogri Gala moves to Executive Director effective Oct 1, pending AGM approval. Prior-year Q1 figures were restated for a derivative fair value loss.
Strong quarterly growth and capacity expansion signal confidence, though funding includes borrowings. Leadership change awaits shareholder approval.